Literature DB >> 3501513

Tuberculoid leprosy in Mexicans is associated with HLA-DR3.

C Gorodezky, J Flores, N Arevalo, L E Castro, A Silva, O Rodriguez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3501513     DOI： 10.5935/0305-7518.19870042

Source DB:  PubMed          Journal:  Lepr Rev        ISSN： 0305-7518            Impact factor:   0.537


× No keyword cloud information.
  5 in total

1.  Association of HLA antigens with differential responsiveness to Mycobacterium w vaccine in multibacillary leprosy patients.

Authors:  R Rani; S A Zaheer; N R Suresh; R Walia; S K Parida; A Mukherjee; R Mukherjee; G P Talwar
Journal:  J Clin Immunol       Date:  1992-01       Impact factor: 8.317

2.  Association of genetic polymorphism of HLA-DRB1 antigens with the susceptibility to lepromatous leprosy.

Authors:  Monica Escamilla-Tilch; Nora Magdalena Torres-Carrillo; Rosalio Ramos Payan; Maribel Aguilar-Medina; Ma Isabel Salazar; Mary Fafutis-Morris; Roberto Arenas-Guzman; Sergio Estrada-Parra; Iris Estrada-Garcia; Julio Granados
Journal:  Biomed Rep       Date:  2013-09-19

Review 3.  Infectious diseases and immunity: special reference to major histocompatibility complex.

Authors:  N Singh; S Agrawal; A K Rastogi
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

4.  Human leukocyte antigen class I and class II alleles are associated with susceptibility and resistance in borderline leprosy patients from Southeast Brazil.

Authors:  Fabiana Covolo de Souza-Santana; Elaine Valim Camarinha Marcos; Maria Esther Salles Nogueira; Somei Ura; Jane Tomimori
Journal:  BMC Infect Dis       Date:  2015-01-21       Impact factor: 3.090

5.  Evidence for an association of HLA-DRB1*15 and DRB1*09 with leprosy and the impact of DRB1*09 on disease onset in a Chinese Han population.

Authors:  Furen Zhang; Hong Liu; Shumin Chen; Changyuan Wang; Chuanfu Zhu; Lin Zhang; Tongsheng Chu; Dianchang Liu; Xiaoxiao Yan; Jianjun Liu
Journal:  BMC Med Genet       Date:  2009-12-11       Impact factor: 2.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.